

# Omnis US Smaller Companies Fund

A Income Class - 28 March 2024



## Investment objective

The Fund aims to achieve a return consisting of both income and capital growth, which, after all fees and expenses, exceeds that of the Russell 2500 TR Index over a five-year rolling period.

## Investment policy

The sub-fund intends to invest at least 70% in the equity securities of smaller US companies defined as those which are domiciled, incorporated or have a significant exposure to the US and which have a market capitalisation no greater than the largest company in the Russell 2500 TR index at the time of the Fund's investment.

The Fund may also invest in other transferable securities (for example, equity securities of other international companies), units in collective investment schemes (including schemes managed and operated by the ACD or its associates), money market instruments, warrants, cash and near cash deposits as detailed in the Prospectus.

Derivatives may be used for the purposes of hedging and efficient portfolio management.

## About Omnis Investments

Omnis Investments Limited is wholly owned by Openwork Holdings Limited, bringing established specialist providers together to create a tailored investment solution. It is focused on delivering maximum returns to investors for well-defined levels of risk via a series of funds.

## Fund breakdown

### Sector breakdown (%)

Industrials	21.17
Information Technology	16.39
Health Care	12.04
Financials	12.02
Consumer Discretionary	9.72
Materials	8.85
Energy	7.81
Real Estate	6.75
Utilities	1.89
Others	3.35



### Top 10 Holdings (%)

Vulcan Materials	1.68
Teledyne Technologies	1.64
Element Solutions Inc	1.52
Waste Connections	1.36
Vontier Corp	1.27
Reliance Steel & Aluminum Co	1.25
Atmos Energy Corp	1.22
Arthur J Gallagher & Co.	1.21
Diamondback Energy Inc	1.20
SPX Technologies	1.15

## Fund details

Inception date 24 August 2019

AUM £130.99m

Base currency Pounds Sterling

Benchmark  
Russell 2500 TR Index

## Share class details

ISIN GB00BJRD8C20

SEDOL BJRD8C2

Ongoing charges figure\* 0.97

Fund price 161.11p

Yield 0.11%

\*Data as at 31/12/2023

## Distribution rates

Share class	Pay dates	Rates
A Inc Class	30 Nov 2023	0.0662
A Inc Class	31 May 2023	0.1072

## Investment manager

**T.RowePrice®**  
INVEST WITH CONFIDENCE

T. Rowe Price International Limited  
Sub-delegated to: T. Rowe Price Investment Management



Curt Organt



Matt Mahon

Curt Organt joined T.Rowe Price in 1995 and is portfolio manager of the US Smaller Companies Equity Strategy. Prior to this he was a financial analyst and a marketing analyst at DAP Products, Inc. Curt earned a B.S. in Finance and Philosophy from La Salle University and an M.B.A. from Wake Forest University. He is also a Chartered Financial Analyst.

Matt Mahon is co-portfolio manager of the US Smaller Companies Equity Strategy. Matt's has been with T. Rowe Price since 2016, previously spending four years as an investment analyst at Water Street Capital, Inc., a long/short equity hedge fund. Matt earned an M.B.A. from the University of Pennsylvania, The Wharton School, where he received the Henry Ford II Fellowship and was a Palmer Scholar. He also earned a B.S. in Finance from Wake Forest University, where he received the Wall Street Journal Achievement Award.

# Omnis US Smaller Companies Fund

A Income Class - 28 March 2024



## Fund Performance

### Performance since launch (%)



### Cumulative performance (%)

	1 month	3 months	6 months	1 year	3 years	Since launch
Fund	4.42	6.09	16.69	22.40	22.26	61.32
Benchmark	4.27	7.90	17.10	18.86	19.25	59.51

### Discrete annual performance as at 28/03/2024 (%)

	31/03/2023 31/03/2024	31/03/2022 31/03/2023	31/03/2021 31/03/2022	31/03/2020 31/03/2021	31/03/2019 31/03/2020
Fund	22.40	-6.00	6.25	55.90	-
Benchmark	18.86	-4.58	5.15	70.22	-

### Calendar performance (%)

	2023	2022	2021	2020	2019
Fund	15.42	-10.01	17.58	25.76	-
Benchmark	10.80	-8.08	19.27	16.29	-

Source: FE Analytics as at 28 March 2024

All performance in this factsheet is based on income shares with income reinvested, in GBP. Past performance is not indicative of future results.

**Important information:** All information correct as at 28 March 2024. Please note that the value of an investment may go down as well as up and an investor may not get back the full amount invested. The Omnis Portfolio Investments ICVC is an authorised Investment Company with Variable Capital. The authorised corporate director of the Omnis Portfolio Investments ICVC is Omnis Investments Limited (Registered Office, Auckland House, Lydiard Fields, Swindon, SN5 8UB) which is authorised and regulated by the Financial Conduct Authority. This document has been issued and approved for the purposes of section 21 of the Financial Services and Markets Act 2000 by Omnis Investments Limited. Omnis Investments Limited is registered in England and Wales under registration number 06582314. Omnis Investments Limited does not offer investment advice nor make recommendations regarding investments. Potential investors are particularly advised to read the specific risks and charges applicable to the Fund which are contained in the Key Investor Information Document (KIID). The KIID and Supplementary Information Document (SID) are available from Omnis Investments Limited at [www.omnisinvestments.com](http://www.omnisinvestments.com) or by telephoning 0345 140 0070 during normal business hours. The full Prospectus is also available on the Omnis Investments Limited website.

Source: London Stock Exchange Group plc and its group undertakings (collectively, the "LSE Group"). © LSE Group 2023. FTSE Russell is a trading name of certain of the LSE Group companies. All rights in the FTSE Russell indexes or data vest in the relevant LSE Group company which owns the index or the data. Neither LSE Group nor its licensors accept any liability for any errors or omissions in the indexes or data and no party may rely on any indexes or data contained in this communication. No further distribution of data from the LSE Group is permitted without the relevant LSE Group company's express written consent. The LSE Group does not promote, sponsor or endorse the content of this communication.